S&P 500   5,088.52 (+-0.01%)
DOW   39,174.31 (+0.11%)
QQQ   437.88 (+0.25%)
AAPL   181.71 (-0.44%)
MSFT   409.64 (-0.17%)
META   483.14 (-0.18%)
GOOGL   140.09 (-2.69%)
AMZN   175.78 (+0.45%)
TSLA   197.49 (+2.88%)
NVDA   797.31 (+1.16%)
NIO   5.69 (+5.37%)
AMD   176.35 (-0.10%)
BABA   76.47 (+0.67%)
T   16.62 (-1.07%)
F   12.17 (+0.25%)
MU   90.17 (+4.85%)
CGC   3.48 (+3.57%)
GE   154.69 (+0.89%)
DIS   108.44 (+0.65%)
AMC   4.55 (+2.48%)
PFE   27.24 (-1.87%)
PYPL   59.79 (+1.06%)
XOM   104.68 (+0.81%)
S&P 500   5,088.52 (+-0.01%)
DOW   39,174.31 (+0.11%)
QQQ   437.88 (+0.25%)
AAPL   181.71 (-0.44%)
MSFT   409.64 (-0.17%)
META   483.14 (-0.18%)
GOOGL   140.09 (-2.69%)
AMZN   175.78 (+0.45%)
TSLA   197.49 (+2.88%)
NVDA   797.31 (+1.16%)
NIO   5.69 (+5.37%)
AMD   176.35 (-0.10%)
BABA   76.47 (+0.67%)
T   16.62 (-1.07%)
F   12.17 (+0.25%)
MU   90.17 (+4.85%)
CGC   3.48 (+3.57%)
GE   154.69 (+0.89%)
DIS   108.44 (+0.65%)
AMC   4.55 (+2.48%)
PFE   27.24 (-1.87%)
PYPL   59.79 (+1.06%)
XOM   104.68 (+0.81%)
S&P 500   5,088.52 (+-0.01%)
DOW   39,174.31 (+0.11%)
QQQ   437.88 (+0.25%)
AAPL   181.71 (-0.44%)
MSFT   409.64 (-0.17%)
META   483.14 (-0.18%)
GOOGL   140.09 (-2.69%)
AMZN   175.78 (+0.45%)
TSLA   197.49 (+2.88%)
NVDA   797.31 (+1.16%)
NIO   5.69 (+5.37%)
AMD   176.35 (-0.10%)
BABA   76.47 (+0.67%)
T   16.62 (-1.07%)
F   12.17 (+0.25%)
MU   90.17 (+4.85%)
CGC   3.48 (+3.57%)
GE   154.69 (+0.89%)
DIS   108.44 (+0.65%)
AMC   4.55 (+2.48%)
PFE   27.24 (-1.87%)
PYPL   59.79 (+1.06%)
XOM   104.68 (+0.81%)
S&P 500   5,088.52 (+-0.01%)
DOW   39,174.31 (+0.11%)
QQQ   437.88 (+0.25%)
AAPL   181.71 (-0.44%)
MSFT   409.64 (-0.17%)
META   483.14 (-0.18%)
GOOGL   140.09 (-2.69%)
AMZN   175.78 (+0.45%)
TSLA   197.49 (+2.88%)
NVDA   797.31 (+1.16%)
NIO   5.69 (+5.37%)
AMD   176.35 (-0.10%)
BABA   76.47 (+0.67%)
T   16.62 (-1.07%)
F   12.17 (+0.25%)
MU   90.17 (+4.85%)
CGC   3.48 (+3.57%)
GE   154.69 (+0.89%)
DIS   108.44 (+0.65%)
AMC   4.55 (+2.48%)
PFE   27.24 (-1.87%)
PYPL   59.79 (+1.06%)
XOM   104.68 (+0.81%)
NASDAQ:GRCL

Gracell Biotechnologies (GRCL) Stock Price, News & Analysis

$10.25
+0.01 (+0.10%)
(As of 02/22/2024 08:00 PM ET)
Today's Range
$10.17
$10.28
50-Day Range
$5.65
$10.35
52-Week Range
$1.40
$10.44
Volume
6.42 million shs
Average Volume
1.32 million shs
Market Capitalization
$744.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.04

Gracell Biotechnologies MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
27.2% Upside
$13.04 Price Target
Short Interest
Healthy
1.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.61mentions of Gracell Biotechnologies in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.92) to ($0.97) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.00 out of 5 stars

Medical Sector

374th out of 935 stocks

Pharmaceutical Preparations Industry

168th out of 428 stocks


GRCL stock logo

About Gracell Biotechnologies Stock (NASDAQ:GRCL)

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China.

GRCL Stock Price History

GRCL Stock News Headlines

Gracell Biotechnologies Acquisition Completed
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Gracell Biotechnologies Acquisition Completed
Gracell Biotechnologies Inc. (GRCL)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
GRCL Mar 2024 2.500 call
GRCL Gracell Biotechnologies Inc.
See More Headlines
Receive GRCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gracell Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2021
Today
2/26/2024
Next Earnings (Estimated)
3/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GRCL
Fax
N/A
Employees
314
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.04
High Stock Price Target
$20.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+27.2%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
8 Analysts

Profitability

Net Income
$-88,080,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$60,000.00
Price / Sales
12,415.83
Book Value
$2.95 per share

Miscellaneous

Free Float
52,328,000
Market Cap
$744.95 million
Optionable
Optionable
Beta
-0.33
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report














GRCL Stock Analysis - Frequently Asked Questions

Should I buy or sell Gracell Biotechnologies stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gracell Biotechnologies in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GRCL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRCL, but not buy additional shares or sell existing shares.
View GRCL analyst ratings
or view top-rated stocks.

What is Gracell Biotechnologies' stock price target for 2024?

8 brokerages have issued 1-year target prices for Gracell Biotechnologies' stock. Their GRCL share price targets range from $10.00 to $20.00. On average, they anticipate the company's stock price to reach $13.04 in the next twelve months. This suggests a possible upside of 27.2% from the stock's current price.
View analysts price targets for GRCL
or view top-rated stocks among Wall Street analysts.

How have GRCL shares performed in 2024?

Gracell Biotechnologies' stock was trading at $10.04 at the start of the year. Since then, GRCL shares have increased by 2.1% and is now trading at $10.25.
View the best growth stocks for 2024 here
.

Are investors shorting Gracell Biotechnologies?

Gracell Biotechnologies saw a increase in short interest in January. As of January 31st, there was short interest totaling 1,190,000 shares, an increase of 171.6% from the January 15th total of 438,200 shares. Based on an average daily volume of 1,260,000 shares, the days-to-cover ratio is currently 0.9 days. Currently, 1.6% of the shares of the stock are sold short.
View Gracell Biotechnologies' Short Interest
.

When is Gracell Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024.
View our GRCL earnings forecast
.

How were Gracell Biotechnologies' earnings last quarter?

Gracell Biotechnologies Inc. (NASDAQ:GRCL) announced its quarterly earnings results on Sunday, November, 14th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.18. The firm had revenue of $0.06 million for the quarter.

When did Gracell Biotechnologies IPO?

(GRCL) raised $150 million in an initial public offering on Friday, January 8th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities served as the underwriters for the IPO.

Who are Gracell Biotechnologies' major shareholders?

Gracell Biotechnologies' stock is owned by many different institutional and retail investors. Top institutional investors include Vivo Capital LLC (13.13%), TIG Advisors LLC (1.76%), Alpine Associates Management Inc. (1.76%), Octagon Capital Advisors LP (0.82%), Sphera Funds Management LTD. (0.69%) and MMCAP International Inc. SPC (0.62%).

How do I buy shares of Gracell Biotechnologies?

Shares of GRCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GRCL) was last updated on 2/26/2024 by MarketBeat.com Staff